FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

Spinogenix’s first-in-class ALS treatment, SPG302 has been shown to slow disease progression in 82% of patients during a Phase IIa study. 

Cencora to invest $1bn in US pharma distribution network

Celltrion Signs Licensing Deal with U.S. Kaigene for Two Antibody Drug Candidates

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy